AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: medicines

newssourceFORcompanyinformationcontent1marketreleases

Inside information: Orion upgrades full-year outlook for 2025

ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
9 JULY 2025 at 13.00 EEST
        

Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine

PRAGUE, July 9, 2025 /PRNewswire/ -- Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of...

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Alvotech acquires capability and added flexibility in assembly and packaging with acquisition of Ivers-Lee Group

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Genfit : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 8 juillet 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial.

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

CARLSBAD, Calif., July 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities...

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Medicines for Poland gibt bekannt: Ohne pharmazeutische Fabriken wird Europa jeden Krieg verlieren

BRÜSSEL, July 08, 2025 (GLOBE NEWSWIRE) -- Die Notwendigkeit, einen Fonds aus dem EU-Haushalt einzurichten, um die Produktion kritischer Arzneimittel in Europa zu unterstützen, ist eine Schlussfolgerung aus einer Analyse der Auswirkungen des Krieges auf die Verfügbarkeit von Arzneimitteln in der Ukraine. Medicines for Poland: Die Europäische Kommission sollte die bestehende Pharmaindustrie in Europa konkret unterstützen, um die Verlagerung der Produktion kritischer Arzneimittel und ihrer Inhaltsstoffe zurück in die EU zu ermöglichen, wobei der Schwerpunkt auf Mittel- und Osteuropa als Region mit hohem industriellem Potenzial liegen sollte.

Novartis receives approval for first malaria medicine for newborn babies and young infants

Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...

INOVIO to Present at Upcoming Scientific Conference

PLYMOUTH MEETING, Pa., July 7, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers